Daily Turnover | The turnover of Capricor on 10/1 was $200.60 Million, Ranking 398

The turnover of Capricor on 10/1/2024 was $200.60 million, ranking 398 in today's market, the Volume is 12.84 million.

Capricor(CAPR) shares closed at $15.01, down 1.31% on 10/1/2024, up 64.95% in the last 5 trading days, down 1.31% this month, up 206.95% year-to-date and up 417.59% in the last 52 weeks.
*If the company has been listed for less than 52 weeks, the 52-week gain is the gain since the listing.
(The same applies for less than 1 month, or less than 5 trading days)

【History Turnover】

Date	Turnover	Volume	Price	Performance
10/1/2024	$200.60 million	12.84 million	$15.01	-1.31%
9/30/2024	$208.98 million	15.34 million	$15.21	52.86%
9/27/2024	$24.47 million	2.55 million	$9.95	-0.40%
9/26/2024	$59.73 million	5.81 million	$9.99	-3.38%
9/25/2024	$483.37 million	41.98 million	$10.34	13.63%

【Company Profile】
Capricor Therapeutics, Inc. was registered and established in Delaware. The company is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy, or DMD, a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. Since inception, the company have devoted substantial resources to developing CAP-1002 and they other product candidates including they exosomes platform, developing they manufacturing processes, staffing the company and providing general and administrative support for these operations. The company do not have any products approved for sale. The company ability to eventually generate any product revenue sufficient to achieve profitability will depend on the successful development, approval and eventual commercialization of CAP-1002 for the treatment of DMD and they other product candidates.